A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
Authors:
- Alexandre HarariAHAlexandre Harari
- Apostolos SarivalasisASApostolos Sarivalasis
- Kaat de JongeKJKaat de Jonge
- Anne-Christine ThierryATAnne-Christine Thierry
- Florian HuberFHFlorian Huber
- Caroline BoudousquieCBCaroline Boudousquie
- Laetitia RossierLRLaetitia Rossier
- Angela OrcurtoAOAngela Orcurto
- Martina ImbimboMIMartina Imbimbo
- Petra BaumgaertnerPBPetra Baumgaertner
- Michal Bassani-SternbergMBMichal Bassani-Sternberg
- Lana E. KandalaftLKLana E. Kandalaft
Open Access
Abstract
Endometrial cancer (EC) is a common gynecological malignancy and the fourth most common malignancy in European and North American women. Amongst EC, the advanced serous, p53-mutated, and pMMR subtypes have the highest risk of relapse despite optimal standard of care therapy. At present, there is no standard of care maintenance treatment to prevent relapse among these high-risk patients. Vaccines are a form of immunotherapy that can potentially increase the immunogenicity of pMMR, serous, and p53-mutated tumors to render them responsive to check point inhibitor-based immunotherapy. We demonstrate, for the first time, the feasibility of generating a personalized dendritic cell vaccine pulsed with peptide neoantigens in a patient with pMMR, p53-mutated, and serous endometrial adenocarcinoma (SEC). The personalized vaccine was administered in combination with systemic chemotherapy to treat an inoperable metastatic recurrence. This treatment association demonstrated the safety and immunogenicity of the personalized dendritic cell vaccine. Interestingly, a complete oncological response was obtained with respect to both radiological assessment and the tumor marker CA-125.Keywords
This publication has 37 references indexed in Scilit:
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive MelanomaJournal of Clinical Oncology, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid TumorsJournal of Clinical Oncology, 2009
- Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancerGynecologic Oncology, 2009
- Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigenProceedings of the National Academy of Sciences, 2008
- An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesJournal of Experimental Medicine, 2008
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProceedings of the National Academy of Sciences, 2007
- Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsProceedings of the National Academy of Sciences, 2006
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000